• 10-Year Study on CARTO/PARTO for Gastric Variceal Bleeding

    A multi-center study across 13 centers in five countries evaluated the long-term outcomes of CARTO/PARTO for gastric variceal (GV) bleeding in 311 patients over 10 years.The results show excellent survival…

  • Advancing Esophageal Cancer Treatment

    Professor Florian Lordick played a key role in the ESOPEC trial, a landmark phase 3, multicenter, randomized study published in The New England Journal of Medicine. This trial directly compared perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) to preoperative chemoradiotherapy (carboplatin, paclitaxel, and radiotherapy) in patients with resectable esophageal adenocarcinoma, aiming to determine…

  • Consensus Best Practices for Neoadjuvant Therapy in Pancreatic Cancer

    A panel of 47 North American experts has developed 82 consensus best practices for delivering neoadjuvant therapy in pancreatic ductal adenocarcinoma, using a modified Delphi process to standardize and optimize care. This effort aims to improve treatment approaches, reduce variability in care, and enhance patient outcomes. The study outlines best practices across the entire neoadjuvant…

  • NCCN Breast Cancer Guidelines (Version 3.2024): Advancing Multidisciplinary Care

    The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer provide essential recommendations for managing carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer,…

  • Immunohistochemical Status Predicts Response to Neoadjuvant Therapy in HER2+ Breast Cancer

    In December 2024 a publication in the Annals of Surgical Oncology analyzed data from the National Cancer Database, showing that HER2 IHC3+ patients had significantly higher pathologic complete response (pCR)…

  • Advancing Immunotherapy in Refractory Colorectal Cancer

    In the pursuit of improving outcomes for patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC), Dr. Filippo Pietrantonio has made significant contributions through groundbreaking research exploring the potential of combining vorbipiprant, a prostaglandin EP4 antagonist, with PD-1 blockade therapy.

  • Exploring Real-World Outcomes in BRAF V600E-Mutated Metastatic Colorectal Cancer

    This real-world study sheds light on the clinical outcomes of patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI). Conducted across Spain and Italy, the study evaluated 26 patients, offering valuable insights into survival outcomes and treatment-related adverse events in routine clinical practice.

  • SEOM-GEMCAD-TTD Clinical Guidelines for the Adjuvant Treatment of Colon Cancer (2023)

    The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.